伊维菌素治疗与无症状SARS-CoV-2感染者病毒RNA载量变化相关:一项随机对照试验
该随机对照试验纳入126例无症状SARS-CoV-2阳性受试者,比较标准护理(锌和维生素C)与标准护理加单剂伊维菌素的效果。96小时后伊维菌素组Ct值平均增加8.38(95%CI 7.56-9.20),对照组增加3.19(95%CI 2.36-4.02),组间差异5.19(95%CI 3.72-6.66,p<0.001)。伊维菌素组报告的症状更少、住院率更低,但临床趋势需谨慎解读。
要点
- 单剂伊维菌素使无症状感染者96小时Ct值平均增加8.38,对照为3.19。
- 伊维菌素组症状报告更少、住院率更低,但临床趋势需谨慎解读。
- 结论需大规模多中心随机试验确认。
核心结论
- 单剂口服伊维菌素可能加速无症状SARS-CoV-2阳性个体的病毒清除并减少症状进展。
- 需进一步大规模多中心随机试验确认这些发现并评估伊维菌素在早期COVID-19管理中的潜在作用。
研究设计与样本
- 随机对照试验,纳入126例无症状SARS-CoV-2阳性受试者。
- 受试者分为标准护理(锌和维生素C补充)组或标准护理加单剂伊维菌素组。
- 采用逆转录PCR评估96小时后循环阈值(Ct)值变化,并监测临床症状发展和住院率。
主要发现
- 基线Ct值两组相似。
- 96小时后伊维菌素组Ct值从15.97±2.823增至24.35±3.086,对照组从16.65±3.593增至19.84±3.743(p<0.001)。
- 伊维菌素组Ct值平均增加8.38(95%CI 7.56-9.20),对照组平均增加3.19(95%CI 2.36-4.02),平均差异5.19(95%CI 3.72-6.66;p<0.001)。
- 伊维菌素组报告的症状(如嗅觉丧失、疲劳、肌痛)更少,住院率更低,但临床趋势需谨慎解读。
关键数值与推荐
- 单剂口服伊维菌素剂量按体重调整。
- Ct值变化为96小时逆转录PCR检测结果。
临床怎么用
- 目前证据尚不足以推荐伊维菌素常规用于无症状SARS-CoV-2感染者的早期管理。
- 临床决策应等待更大规模多中心随机试验的确认。
局限性
- 样本量较小(126例),需更大规模多中心试验确认。
- 临床趋势(症状减少、住院率降低)需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ivermectin, an antiparasitic agent with reported antiviral properties, has been investigated for repurposing in the treatment of COVID-19. This study aimed to assess the efficacy of a single weight-adjusted oral dose of ivermectin in reducing viral load and improving clinical outcomes in asymptomatic individuals infected with SARS-CoV-2. METHODS: A randomized controlled trial was conducted with 126 asymptomatic SARS-CoV-2-positive participants. Subjects were assigned to receive either standard care (zinc and vitamin C supplementation) or standard care plus a single dose of ivermectin. Reverse transcription-PCR was used to assess changes in cycle threshold (Ct) values after 96 h. Clinical symptom development and hospitalization rates were also monitored. RESULTS: Baseline Ct values were similar between groups. After 96 h, participants in the ivermectin group showed a greater increase in Ct values (from 15.97 ± 2.823 to 24.35 ± 3.086) compared with controls (from 16.65 ± 3.593 to 19.84 ± 3.743; p < 0.001), the mean increase in Ct was 8.38 (95% CI, 7.56-9.20) in the ivermectin group versus 3.19 (95% CI, 2.36-4.02) in the control group (mean difference 5.19 (95% CI, 3.72 to 6.66); p < 0.001), suggesting a potential for more rapid reduction in viral load. Participants receiving ivermectin also reported fewer symptoms (e.g., anosmia, fatigue, myalgia) and had a lower hospitalization rate, though these clinical trends should be interpreted cautiously. CONCLUSION: A single oral dose of ivermectin may accelerate viral clearance and reduce symptom progression in asymptomatic SARS-CoV-2-positive individuals. Further large-scale, multi-center randomized trials are warranted to confirm these findings and evaluate ivermectin's potential role in early COVID-19 management. TRIAL REGISTRATION: This randomized controlled trial was conducted between November and December 2021 and was registered in the World Health Organization Clinical Trial Registry (ChiCTR2000033627; Date of Registration: 2020-06-07).
引用
- Mouawia H, Saab HB, Ayoub H, et al. Ivermectin therapy is associated with changes in SARS-CoV-2 RNA load in asymptomatic patients: a randomized controlled trial. Trials. 2026. PMID: 42063155. doi:10.1186/s13063-026-09736-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。